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Abstract
Intracerebral hematoma occurs in about 35/100,000 population and the incidence is likely 
increase over the next few decades as the population ages. The most common causes are 
hypertension and amyloid angiopathy. Bleeds due to these two causes are classified as 
primary while all other causes, such as AVM bleeds, coagulopathies, and so on, are classi‐
fied as secondary. Primary tissue damage due to the intracerebral hematoma is followed 
by edema, neuronal damage, and secondary damage due to cellular breakdown. Basal 
ganglia are the most common site of intracerebral hemorrhage, accounting for nearly 
50% of cases. CT scan, CT angiogram, DSA, and MRI are the investigations of choice. The 
initial management is medical, with control of blood pressure and antiedema measures 
forming the mainstay of treatment. Surgical option includes external ventricular drain‐
age, endoscopic evacuation of hematoma, craniotomy and evacuation of hematoma, and 
decompressive craniectomy and is usually reserved for patients who deteriorate while 
on treatment.
Keywords: intracerebral hematoma, management, guidelines
1. Epidemiology
Intracerebral hemorrhage (ICH) or hemorrhage within the brain parenchyma is the second 
most common cause of all cases of sudden neurological deficits following strokes and has the 
highest mortality amongst all varieties of stroke [1]. A study in 1993 [2] showed that 1‐year 
survival following an ICH was 38% and this had improved to only 52% by 2009 [3]. In‐hospi‐
tal mortality has remained stable at around 34% over the last three decades [4], all of which 
makes prevention a cornerstone of treatment of this devastating disease. The incidence of ICH 
in the United States is estimated to be about 24.6/100,000 of person years, ranging from 1.8 to 
129 per 100,000 person years [5] and this is likely to go up over the next few decades as the 
percentage of the elderly in the population increases.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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One of the major risk factors identified with ICH has been that of race, with Asian popula‐
tions being affected almost twice as much as other races. Whites appear to have a lower inci‐
dence when compared to nonwhites. The second risk factor to be identified was age, with 
those over 85 years of age having a 10‐fold increase in the incidence of ICH compared to 
younger patients. Women were found to have a 15% lower chance of hemorrhages, but this 
was not statistically significant [6]. The single most important modifiable risk factor associ‐
ated with ICH has undeniably been hypertension. A meta‐analysis of 11 case control studies 
found the risk of bleeding in hypertensives to be 3.5 times above that in normotensives [7] 
while a multicentric case control study put the risk at nine times above that in normoten‐
sives in patients who had a blood pressure of over 160/90 mm Hg [8]. Even increases within 
the normal range of blood pressure have been associated with a linear increase in the risk 
of ICH [9].
Increased alcohol intake in the 24 hours preceding the onset of bleed as well as during the 
week prior to the ictus have been identified as independent risk factors for ICH [10] and the 
location of the hematoma in these patients tended to be lobar [11]. While high cholesterol 
levels have been associated with increased risk for ischaemic stroke, low cholesterol has been 
associated with an increased risk of cerebral micro bleeds and ICH. However, the exact associ‐
ation of different lipid fractions with this risk has yet to be elucidated [12]. Recent studies have 
shown that apolipoprotein E (APOE) ε2 and ε4 are independent risk factors for lobar ICH, 
which stands to reason considering their association with amyloidosis [13]. Tobacco smoking 
has been consistently associated with occlusive diseases such as coronary and peripheral vas‐
cular disease, as well as ischaemic stroke and subarachnoid hemorrhage, but its association 
with ICH is tenuous at best [14].
2. Etiology
ICH has been divided into primary and secondary varieties based on the underlying pathol‐
ogy. When no underlying pathology such as vascular malformation or coagulopathy is 
detected, and the primary cause of the bleed is due to rupture of small vessels in the brain, 
usually secondary to chronic damage from long‐standing hypertension or cerebral amyloid 
angiopathy, the bleed is considered primary (Figures 1 and 2). Nearly 80% of all intracerebral 
hematoma cases fall into this category [15].
Chronically elevated blood pressure causes smooth cell hyperplasia in the cerebral arteries, 
followed by death of smooth muscle cells. There is also an increase in the stiffness of arterial 
walls in these patients, and this loss of elasticity may predispose to arterial rupture with sudden 
elevations in blood pressure. Electron microscopic studies have shown that most ruptures occur 
near the bifurcation of arteries, where there is degeneration of tunica media. This may be why 
most of the bleeds that occur in hypertension are located in deeper parts of the brain [16, 17]. 
Cerebral amyloid angiopathy, in contrast, features amyloid deposition in the leptomeningeal 
and intraparenchymal cortical vessels, resulting in superficial or lobar hemorrhages. Patients 
with amyloidosis are more likely to be older (over 60 years of age) and have hematoma sizes 
greater than 30 cc while those with hypertension are younger and have hematoma volumes less 
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than 30 cc [18]. A history of recurrent episodes of intracranial bleeds is likely to favor a diagnosis 
of cerebral amyloid angiopathy. It should, however, be borne in mind that these characteristics 
are nonspecific and need to be confirmed by histopathology if possible [19].
Bleeding from vascular malformations such as arteriovenous malformation (Figure 3), cav‐
ernous angiomas, and dural arteriovenous (AV) fistulae, hemorrhagic conversion of an isch‐
emic stroke, bleeding from intraparenchymal tumors, ICH occurring in patients with bleeding 
diathesis and in those taking anticoagulants (Figure 4) all come into the category of secondary 
ICH [20]. Tumor bleeds typically occur in metastases, such as melanoma, choriocarcinoma, 
renal carcinoma, or thyroid carcinoma, and from high grade gliomas [21]. Aneurysmal bleeds 
Figure 1. Hypertensive left ganglionic hematoma with IVH.
Figure 2. Same patient as in Figure 1, after surgical evacuation of hematoma following neurological deterioration. The 
black arrow shows widening of Sylvian fissure, which was split to approach the hematoma from its most superficial 
area. The bone flap was not replaced due to severe brain swelling.
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Figure 4. Isolated IVH in an anticoagulated patient.
Figure 3. Large lobar hematoma with IVH due to a vascular malformation.
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(Figure 5) may sometimes present with an intraparenchymal component and an ICH may 
occasionally be the result of a sinus thrombosis [22]. Recently, patients with hepatitis C infec‐
tion have been identified as having a higher risk of ICH compared to a control group without 
HCV infection. The risk was higher in younger patients and increased with increasing sever‐
ity of the viral infection [23]. Drug abuse, especially cocaine use, has been found to cause 
an increased incidence of subcortical hemorrhages with intraventricular extension and these 
Figure 5. This patient had a bleed which looked like a ganglionic hematoma with IVH, but closer observation showed a 
partially thrombosed MCA aneurysm (white arrows, top right).
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patients have a poorer prognosis when compared to nondrug users with spontaneous ICH 
[24]. Patients or oral warfarin have an 8‐ to 14‐fold increase in the risk of ICH compared to the 
normal population, but the risk appears to be lower in those being treated with newer antico‐
agulants such as dabigatran [25, 26].
3. Pathophysiology
Intracerebral hemorrhage results in primary damage due to the injury to neural tissues. This 
is followed by secondary damage resulting from increased intracranial pressure as well as 
the presence of intraparenchymal blood. The secondary damage occurs through several 
pathways that run concurrently, eventually leading to the loss of the blood brain barrier and 
severe cerebral edema resulting in extensive cellular lysis. As in traumatic brain injury, early 
removal of the hematoma and cellular debris, either by surgical removal of the clot or by the 
action of the inflammatory cells such as microglia and macrophages, help to reduce the extent 
of secondary damage [27, 28]. Animal studies have shown that perihematoma edema can be 
divided into three phases: immediate (up to 24 h after hemorrhage), intermediate (from 24 h 
to 5 days), and late (beyond 5 days) [29]. The immediate edema results from osmotically active 
proteins accumulating in the extravascular compartment and can be seen on histological stud‐
ies, but not on imaging. Intracerebral hemorrhage results in primary damage due to the injury 
to neural tissues. This is followed by secondary damage resulting from increased intracranial 
pressure as well as the presence of intraparenchymal blood. The secondary damage occurs 
through several pathways that run concurrently, eventually leading to the loss of the blood 
brain barrier and severe cerebral edema resulting in extensive cellular lysis. As in traumatic 
brain injury, early removal of the hematoma and cellular debris, either by surgical removal of 
the clot or by the action of the inflammatory cells such as microglia and macrophages, help 
to reduce the extent of secondary damage [30]. Red cell destruction due to activation of the 
clotting cascade releases thrombin which again causes disruption of the blood brain barrier, 
failure of the sodium pump, and increase in the edema [31, 32]. This intermediate edema can 
be visualized radiologically. The late cerebral edema results from oxidative damage due free 
radical release which is a result of cellular destruction and hemoglobin breakdown.
Several additional pathways for cellular damage following intracerebral hemorrhage have been 
advocated, such as apoptosis or programmed cell death associated with the expression of nuclear 
factor‐kB in neuronal nuclei [33] and breakdown of extravasated heme into bilirubin and biliru‐
bin oxidation products, which activate microglia. The microglia then activate leucocyte adhesion 
molecules on endothelial walls, leading to an influx of leucocytes into the brain. The activated 
microglia produce cytokines which along with the leucocytes mediate further cell injury [34].
The commonest site for an intracerebral hematoma is the basal ganglia, with the putamen 
being the preferred location. Nearly 50% of all ICH cases involve in the basal ganglia, fol‐
lowed by the thalamus, pons, cerebral white matter, and brainstem. The source of bleeding is 
usually a Charcot‐Bouchard micro‐aneurysm, arising from either the lenticulostriate arteries 
in case of putaminal bleeds or thalamoperforators in case of the thalamic bleeds. The parame‐
dian branches of the basilar artery are the source for basilar and cerebellar hemorrhages [35].
Hemorrhagic Stroke - An Update14
4. Presentation
The clinical presentation of intracerebral hemorrhage depends on the location of the bleed 
and its size. Smaller bleeds in non‐eloquent areas may present with headache, nausea, and 
vomiting. Larger hemorrhages into the frontal lobe may be associated with contralateral 
hemiparesis, mainly involving the upper limbs, and aphasia if the dominant lobe is involved. 
Parietal lobe involvement causes contralateral hemisensory impairment with mild hemipa‐
resis and cognitive impairment. Occipital hematomas may present with pain in the ipsilat‐
eral eye and contralateral homonymous hemianopia. Dominant temporal lobe involvement 
causes Wernicke's aphasia which may be associated with poor auditory comprehension, while 
nondominant temporal lobe hemorrhage may be asymptomatic unless it is large enough to 
cause symptoms due to the mass effect. Putaminal hemorrhages may present with a range of 
symptomatology, from minimal pure motor deficits on the contralateral side to severe sen‐
sorimotor impairment, aphasia, neglect, gaze deviation, and impaired level of consciousness. 
These patients have a gradual deterioration in clinical symptoms from the time of onset with 
a 30‐day mortality as high as 50%, but only a small percentage has headache as a present‐
ing symptom [36]. In contrast, nearly 30% of patients with a thalamic bleed present with 
headache. They have hemisensory disturbances that are out of proportion to the minimal 
weakness. Significant weakness may be found when the hematoma extends into the internal 
capsule and associated eye signs indicate involvement of the midbrain.
Tanaka et al. [37] found that when compared to putaminal hemorrhages, thalamic hemor‐
rhages were associated with a more pronounced reduction in cerebral blood flow (CBF) 
Figure 6. Preoperative images of a vermian hematoma with intraventricular extension in a patient with hemophilia.
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bilaterally, even though their hematoma volumes were much smaller. They hypothesized 
that the reduction of CBF may be secondary to metabolic depression due to transneuronal or 
functional depression (“diaschisis”). The metabolic depression in thalamic hemorrhages is 
more extensive and persistent than in putaminal hemorrhages, which probably accounts for 
the reduced CBF and worse outcome in thalamic hemorrhages. While several studies have 
quoted a size of 3.3 cm as a determinant for survival in patients with thalamic hemorrhages 
[38–40] in a prospective trial that included 100 patients there were three survivors with hema‐
tomas larger than 3.3 cm who were able to lead independent lives [41]. However, sizes of the 
hematoma and intraventricular extension were two major factors that were found to correlate 
with the eventual outcome.
Cerebellar ICH may present with limb ataxia, ipsilateral gaze palsy, cranial nerve deficits 
such as an abducens or peripheral facial palsy, and nonspecific symptoms like headache and 
vomiting. In a series of 56 patients, Ott et al. found that nearly three‐fourth of the patients had 
one of the first three signs described [42]. As in other types of ICH, intraventricular extension, 
initial GCS, and older age were associated with a poor prognosis in patients with cerebellar 
ICH (Figures 6 and 7) [43].
5. Evaluation
A plain computerized tomography (CT) scan of the brain is the standard investigation per‐
formed in all suspected intracranial pathologies which present as an emergency. In cases 
of ICH, CT scan will usually reveal a hyperdense lesion within the brain parenchyma, with 
Figure 7. Postoperative images of a vermian hematoma with intraventricular extension in a patient with hemophilia.
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possible intraventricular or subarachnoid components. The latter typically occurs with ante‐
rior communicating or middle cerebral artery aneurysms.
The volume of the hematoma can be calculated by the modified ellipsoid volume calculation 
where the anteroposterior (A), right to left (B), and cranio‐caudal lengths of the clot (C) are 
measured. The last (that is, C) is calculated by counting the number of slices in which the clot 
is seen and multiplying it by the slice thickness. The formula (A×B×C)/2 can then be used to 
calculate the clot volume [44]. On multivariate analysis in several studies, initial Glasgow 
Coma Scale score, hematoma volume, and an infratentorial location of hemorrhage were 
found to correlate strongly with the outcome of intracerebral hematoma. Univariate analy‐
sis had also implicated higher initial and 48‐h maximum glucose concentrations, and higher 
percentage of ICH expansion as being significantly associated with poor functional outcome 
at hospital discharge. In anticoagulated patients, the initial INR or the time to INR correction 
did not affect the outcome [45].
Magnetic resonance imaging (MRI) is rarely the investigation of choice in the acute scenario 
due to various reasons. A complete study requires much more time than a CT scan and the 
spontaneous movements of a partially obtunded patient may cause imaging artefacts and 
significantly prolong the imaging time. If the patient worsens clinically while undergo‐
ing imaging, it may be difficult to access him immediately. Initially, it was felt that small 
amounts of hyperacute blood were difficult to visualize in many imaging sequences, but a 
study by Linfante et al. showed that MRI scans were capable of demonstrating a hyperacute 
bleed within 2 h of symptom onset [46]. An advantage of MRI is the ability of gradient echo 
sequences to distinguish hemorrhages of varying ages, which is extremely useful in amyloid 
angiopathy and cavernous angiomas.
While initial investigators believed that the progressive neurological deterioration that 
occurred in the hours following an intracerebral hemorrhage were due to the mass effect 
of the hematoma, radiological studies have shown that early hematoma growth occurs in 
up to 38% of all patients with ICH [47]. This has led to efforts to identify the factors that 
promote rehemorrhage, so as to identify the patients at risk of deterioration, as well as to 
develop management strategies to prevent a rebleed. The major risk factors for a rebleed 
include uncontrolled hypertension with a systolic blood pressure more than 195 mm Hg, a 
previous infarction at the site of the hemorrhage, alcoholism which predisposes to liver dis‐
ease and which in turn leads to coagulopathies, anticoagulant use, high white cell count, and 
hyperthermia [48]. Contrast extravasation on CT angiography was found to correlate well 
with the risk of rehemorrhage [49]. The presence of tiny enhancing foci, known as the “spot 
sign” on axial images of a 3D CT angiogram has been reported to be associated with a higher 
risk of hematoma expansion [50]. This correlation was found to be true especially when the 
Hounsfield units (HU) of these foci were in the range of 192.12 ± 45.97 while patients with spot 
signs having a lower HU of 151.10 ± 25 did not suffer from a hematoma expansion [51]. The 
surgical trial in intracerebral hemorrhage (STICH trial) introduced the concept of a prognos‐
tication score for ICH, which was calculated using the equation (10 × admission GCS) – age 
(years) – (0.64 × clot volume (ml)) [52].
Intracerebral Hematoma
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If there is a suspicion of a vascular anomaly as the main cause of the hemorrhage, and if the 
CT angiogram is noncontributory, a catheter angiogram (cerebral DSA) should be considered.
6. Medical management
The optimum treatment for intracerebral hemorrhage is an area of ongoing research and 
changing guidelines (Table 1). While the STICH trial went some way in answering some of 
the questions regarding the role of surgery, it also raised a number of issues which are yet 
to be resolved [53]. The initial, prehospital and emergency room management for patients 
with ICH is the same as those for patients with ischemic stroke and was elucidated in the 
guidelines published by the American Heart Association (AHA) and the American Stroke 
Association in 2013. A severity score should be calculated as soon as possible, so as to enable 
prognostication (Tables 2 and 3). If facilities for stroke care are not available in the hospital, 
the patient should be transferred to a tertiary care center as early as possible.
No. Problem Recommendation Class of 
evidence
1 Initial presentation in emergency Perform baseline ICH severity score I
2 Differentiate between ischemic and 
hemorrhagic stroke
CT or MRI scan I
3 Possibility of hematoma expansion Contrast CT and CT angiogram to be considered IIb
4 Vascular anomaly CT or MR angiograms (arterial/venous studies) 
and DSA to be considered
IIa
5 Management of coagulation defects Correct coagulopathy or thrombocytopenia with 
appropriate therapy
I
6 Patients on vitamin K antagonists (VKA) Stop VKA, give intravenous vitamin K I
7 Fresh frozen plasma (FFP) or prothrombin 
complex concentrates (PCC)
IIb
8 Patients on heparin Protamine sulphate IIb
9 Patients on newer anticoagulants PCC, factor VIII inhibitor bypassing activity 
(FEIBA) or rFVIIa, hemodialysis and activated 
charcoal if drug was ingested within 2 h
IIb
10 Prevention of deep venous thrombosis  
(DVT)
Intermittent pneumatic compression I
Low molecular weight heparin to be considered 
after 1–4 days once cessation of hematoma 
expansion is documented
IIb
11 Established DVT IVC filter or systemic anticoagulation IIa
12 Hypertension (systolic BP 150–220 mm Hg) 
without contraindication for acute lowering 
of BP
Lower SBP to 140 mm Hg Ia
Hypertension (SBP > 220 mm Hg) Aggressive reduction of SBP IIb
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Component Value Points
Glasgow Coma Scale (total score) 3–4 2
5–12 1
13–15 0
Intracerebral hematoma volume ≥30 cm3 1
<30 cm3 0
Intraventricular hemorrhage Present 1
Absent 0
Origin of intracerebral hematoma Infratentorial 1
Supratentorial 0
Age ≥80 years 1
<80 years 0
Table 2. ICH severity score [89].
No. Problem Recommendation Class of 
evidence
13 High blood sugar Control adequately, avoiding hypoglycemia I
14 Fever Control adequately IIb
15 Seizures Clinical seizures and abnormal EEG in patients 
with altered mental status should be treated
I
Continuous EEG monitoring in patients with 
altered mental status that is out of proportion to 
extent of brain injury
IIa
16 Concurrent cardiac events ECG and cardiac enzymes to be checked IIa
17 Hydrocephalus Ventricular drainage IIa
18 GCS less than or equal to 8, presence of  
IVH
ICP monitoring, maintain CPP at 50–70 mm Hg IIb
19 IVH Intraventricular rtPA‐efficacy uncertain IIb
20 Cerebellar hematoma, neurological 
deterioration
Surgical evacuation I
21 Supratentorial ICH, neurological 
deterioration
Surgical evacuation IIb
Decompressive craniectomy IIb
Minimally invasive clot evacuation‐efficacy 
uncertain
IIb
22 Aspiration pneumonia Screen for dysphagia before starting oral feeds I
Table 1. Evidence‐based recommendations on management.
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The patient has to be admitted into a dedicated stroke unit or an intensive care unit, and inva‐
sive (arterial) blood pressure monitoring should be instituted as soon as possible for control of 
hypertension. The INTERACT2 trial showed a significantly better outcome for patients whose 
systolic blood pressure (SBP) was less than 140 mm Hg compared against a group where the 
SBP was less than 180 mm Hg [54]. Therefore, an SBP of 140 mm Hg should be targeted for all 
patients admitted with ICH. If multiple, long‐term, intravenous access is anticipated, a multi‐
lumen central venous line can be inserted if the coagulation profile is normal.
Patients with a low Glasgow Coma Scale score who are not candidates for early surgery may 
need intracranial pressure monitoring. Using an intraventricular catheter for the same has the 
dual advantage of monitoring pressure and allowing drainage of CSF, for countering acute 
rise in intracranial pressure and in cases of obstructive hydrocephalus due to intraventricular 
hemorrhage. The intraventricular blood may frequently block the catheter, which can be over‐
come by using a thrombolytic agent such as 1 mg of tissue plasminogen activator (tPA) given 
through the catheter, following which the catheter is clamped for 30 min. This can be repeated 
every 8 hours until the third and the fourth ventricles are cleared of blood on CT or until a 
maximum cumulative dose of 20 mg rtPA is reached [55]. Ventricular catheters, however, are 
associated with a higher risk of parenchymal bleeds and infections, and this has to be borne in 
mind while choosing the type of ICP monitoring. In patients with coagulation disorders, the 
coagulation should be corrected and if the patient is on antiplatelet drugs, platelet transfusion 
administered prior to catheter insertion [56].
As the medical management of ICH aims primarily to reduce the intracranial pressure, the 
tenets of management have been borrowed from the experience gained in treating traumatic 
brain injury. Mannitol has been the mainstay in the management of raised ICP for a long 
time, but problems such as rebound phenomenon have led to the increasing use of hypertonic 
saline (23.4%) for the same purpose [57]. Both the drugs can be used in patients with ICH but 
the latter may be more effective [58].
Though initial trials with recombinant activated factor VII (rFVIIa) showed promise in limit‐
ing the hematoma size following early administration of the drug to patients with intracere‐
bral hemorrhage, this was not borne out in phase three trials [59, 60] Furthermore, the use of 
rFVIIa has been associated with an increased incidence of thromboembolic events compared 
Total ICH score (points) Mortality rate (%)
0 0
1 13
2 26
3 72
4 97
5–6 100
Table 3. The total ICH score obtained by adding all the component scores from Table 1 can be used to prognosticate the 
mortality as given below.
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to placebo (7% vs. 2%) and as such the medication is not recommended in noncoagulopathic 
patients (Table 4) [56].
A vast majority of patients with ICH have fever during the postictal period and the incidence 
is higher in those with intraventricular hemorrhage. The duration of fever correlates inversely 
with the patient outcome. Furthermore, cooling the body has been reported to reduce the 
perihematoma edema, and hence body temperature needs to be controlled with medicines or 
external cooling after an ICH [61–63].
Almost all patients admitted in the ICU after an intracranial bleed have stress induced hyper‐
glycemia. This may result in loss of control of blood sugars in a diabetic, or high blood sugars 
in a nondiabetic, both of which are associated with a poor outcome in patients with supra‐
tentorial ICH [64]. A study suggested improved clinical outcomes with tight control of blood 
sugar to the range of 80–110 mg%, but this was found to cause occasional hypoglycemia 
resulting in increased mortality [65, 66]. As such, no specific target is recommended for blood 
sugar control in these patients and the broad recommendation that both hypo‐ and hypergly‐
cemia need to be avoided can probably be met by trying to maintain the blood sugar levels in 
the range of 120–150 mg%, at least till new evidence is available.
Up to 16% of patients have seizures after an ICH and the incidence is higher in those with 
lobar bleeds, probably due to the cortical involvement in this cohort of patients. While the 
incidence of seizures in these patients can be reduced by use of prophylactic anticonvulsants, 
their use has not been associated with any change in long‐term clinical outcome or mortality 
[67–69]. Though some studies had linked the use of antiseizure drugs, particularly phenyt‐
oin, to increased death and disability, probably due to their sedative and cardiovascular side 
effects, a recent study found no such correlation [70–72]. A study of sodium valproate showed 
no difference in the rate of new onset seizures in patients given either a placebo (22.2%) or 
the drug (19.5%) [73]. Therefore, use of prophylactic anticonvulsants is not recommended at 
present.
The co‐occurrence of myocardial infarction and ischemic stroke has been well documented, 
and Sandhu et al. found that 15% of patients admitted to the ICU who had an elevated tro‐
ponin I level in the first 24 h, and that is contributed to an increased mortality [74]. A large 
meta‐analysis of stroke patients put the annual risk of MI at 2.2% for these patients [75]. A 
Therapy Class of evidence
rFVIIa for VKA reversal III
Prophylactic anticonvulsants III
Intraventricular drainage in patients with cerebellar 
hematoma, brainstem compression
III
Early surgery for clot evacuation in a stable patient IIb
Table 4. Therapies not indicated in ICH.
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preventive protocol including cardiac enzymes, ECG, and echocardiogram should be in place 
for the management of patients with ICH.
Many patients with intracerebral hemorrhage have an associated coagulopathy or platelet 
dysfunction, either due to an underlying disease such as factor deficiency or due to the use of 
anticoagulant/antiplatelet medications. The presence of such a coagulopathy must be identi‐
fied and corrective measures taken as soon as the patient is admitted, in order to prevent 
hematoma expansion. The detailed management of patients on oral anticoagulants can be 
obtained from the guidelines published by the American College of Chest Physicians [76].
Intraventricular hemorrhage associated with ICH has been consistently associated with a 
worsening of the eventual patient outcome. While an external ventricular drain is useful in 
draining the blood and treating the obstructive hydrocephalus produced due to obstruction 
of the ventricular pathway by blood clots, this treatment is not very effective in practice due to 
the propensity of blood clots to also block the catheter. The use of local fibrinolytic agents was 
promoted to overcome this problem. The CLEAR‐IVH (clot lysis: evaluating accelerated reso‐
lution of IVH) trial [77] showed that there was a significant reduction in the incidence of cath‐
eter blockage and duration of catheter insertion in patients given intraventricular rtPA. They 
had a lower incidence of permanent CSF diversion procedures, but also suffered a higher 
incidence of rehemorrhage [78, 79]. An alternative to the use of intraventricular catheters is 
the endoscopic clearance of the intraventricular hemorrhage. While studies have not shown 
any improvement in mortality or neurological outcome, patients who underwent endoscopic 
clot evacuation have been reported to have a lower requirement of permanent CSF diversion 
procedures [80].
7. Surgical management
The exact role that surgery plays in the management of ICH remains shrouded in controversy, 
mainly due to the multitude of factors and the heterogeneity of patients that present with 
ICH. The largest studies that looked at the benefit of early surgery for patients with supraten‐
torial ICH did not show any benefit compared to medical management, but detailed analysis 
showed that two subgroups of patients had a better prognosis with surgery. The first were 
those with lobar hemorrhages within 1 cm of the cortical surface and the second were those 
who were assigned a poor prognosis at the time of presentation, using a formula devised for 
the study.
The ideal surgical procedure is also open to question, with the reported procedures including 
craniotomy and evacuation of the hematoma, decompressive craniectomy, minimally inva‐
sive clot evacuation with the use of rtPA (MISTIE II), stereotactic aspiration of the clot and 
needle aspiration of the basal ganglionic hematoma [81–84].
There is more clarity in cases of infratentorial hematoma, with most surgeons in agreement 
that pontine hemorrhages are best managed conservatively (Figure 8). This is due to the diffi‐
culty in surgically accessing the brainstem, the morbidity associated with surgery on the brain 
stem and the high mortality associated with these hemorrhages. However, it has been noted 
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that patients with bleeding cavernous malformations have a much better outcome than those 
in whom the cause of hemorrhage is uncontrolled hypertension, and this subgroup may merit 
surgery [85]. On the other hand, most patients with cerebellar hemorrhages warrant early 
surgery, especially when the clot volume is more than 3 cm. This is due to the direct compres‐
sion of brainstem caused by even small infratentorial hemorrhages, due to the small volume 
of the posterior fossa and the propensity of these bleeds to cause obstructive hydrocephalus. 
Insertion of external ventricular drain to treat the hydrocephalus may seem like a logical 
move, but patients thus treated have had a worse prognosis due to the incidence of reverse 
transtentorial herniation following decompression of the ventricles [86, 87].
While performing a craniotomy for evacuation of ICH, a few points have to be kept in mind [88].
1. Position the patient so that a vertical track from the surface will lead to the hematoma. This 
will reduce the chances of the surgeon becoming disoriented and missing the hematoma.
2. In putaminal hemorrhages, the shortest track will often involve dissecting the Sylvian and 
performing the corticectomy in the insula (see Figure 2).
3. In deep‐seated hematomas, use intraoperative ultrasound or neuronavigation to find the 
shortest track to the clot to avoid excessive damage to normal brain.
4. When there is a large hematoma abutting the Sylvian fissure, a preoperative angiography 
(CTA or DSA) should be done to exclude a middle cerebral artery aneurysm (see Figure 5). 
5. After obtaining hemostasis, increase the blood pressure by 20–30 mm Hg above the base‐
line and ensure there is no bleeding, so as to reduce the risk of rebleed.
6. In most cases, the bone flap can be safely replaced as the brain will be lax once the hema‐
toma is evacuated.
Figure 8. Large hypertensive pontine hemorrhage destroying the entire brainstem.
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8. Conclusion
The goal of treatment in patients with ICH is very similar to that in traumatic brain injury, 
namely, to prevent further damage. This can be achieved by preventing the expansion of 
the hematoma, reducing ischemic and hypoxic damage, removal of the hematoma, and 
management of hydrocephalus when appropriate and effective rehabilitation. Primary 
prevention by controlling hypertension should be a goal of national healthcare programs. 
Many of the strategies used in the management of these patients is in a state of constant 
flux since studies on the subject wind up raising more questions than they answer. It is up 
to the physicians to constantly update themselves on the best management protocols for 
these patients, and to devote some time to clinical research that will shed more light on this 
devastating disease.
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